BioSpace News Archive

Verily Life Sciences, a unit of Alphabet Inc. formerly known as Google Life Sciences, plans to undergo a restructuring that includes cutting about 15% of its workforce and shaking up its C-Suite.

Oramed, a clinical-stage company developing orally available versions of biologic drugs, reported disappointing news regarding its lead candidate, ORMD-0801.

Vertex and Arbor Biotechnologies extend partnership in precision gene editing.

At JPM Wednesday, Ionis CEO Brett Monia touted nine positive late- and mid-stage readouts from 2022 and set up the company’s commercial prospects for 2023.

Mallinckrodt plc today announced that Dr. Peter Richardson, B.Med.Sci., BM, BS, MRCP (UK) has been appointed Executive Vice President and Chief Scientific Officer, effective January 12, 2023.

BIOHM , a leading microbiome company guided by the cutting-edge science of Dr. Mahmoud Ghannoum , announced it has raised a $7.5 million equity financing.

Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce preliminary estimates of the company’s revenue results for the fiscal quarter ended December 31, 2022 (the company’s fiscal Q3 2023) and provide additional business updates to shareholders and other stakeholders.

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the B. Riley Securities 3rd Annual Virtual Oncology Conference on January 18 at 1 p.m. ET.

Cybin Inc. today announced that it has selected Generalized Anxiety Disorder (“GAD”) with or without major depressive disorder (“MDD”) as the target indication for its proprietary deuterated N, N-dimethyltryptamine (“DMT”) molecule, CYB004.

Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate virtually in B. Riley Securities’ 3rd Annual Oncology Conference.